Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy

Clinical Cancer Research

Volumn 20, Issue 7, 2014, Pages 1955-1964

  Voss, Martin H ^a   Hakimi, A Ari ^a   Pham, Can G ^a   Brannon, A Rose ^a   Chen, Ying Bei ^a   Cunha, Luis F ^a   Akin, Oguz ^a   Liu, Han ^a   Takeda, Shugaku ^a   Scott, Sasinya N ^a   Socci, Nicholas D ^a   Viale, Agnes ^a   Schultz, Nikolaus ^a   Sander, Chris ^a   Reuter, Victor E ^a   Russo, Paul ^a   Cheng, Emily H ^a   Motzer, Robert J ^a   Berger, Michael F ^a   Hsieh, James J ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; TEMSIROLIMUS; INDOLE DERIVATIVE; MTOR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PYRROLE DERIVATIVE; SUNITINIB; TARGET OF RAPAMYCIN KINASE; TUBEROUS SCLEROSIS COMPLEX 1 PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER GENETICS; CANCER TISSUE; CLINICAL ARTICLE; DNA EXTRACTION; DRUG SENSITIVITY; EXOME; FEMALE; GENE SEQUENCE; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; MALE; METASTASIS; MIDDLE AGED; MTOR GENE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TREATMENT DURATION; TREATMENT RESPONSE; TSC1 GENE; TUMOR GENE; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CARCINOMA, RENAL CELL; GENETICS; HUMAN GENOME; PATHOLOGY;

AGED; CARCINOMA, RENAL CELL; EXOME; GENOME, HUMAN; HUMANS; INDOLES; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROTEIN KINASE INHIBITORS; PYRROLES; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEINS;

EID: 84898732516     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-2345     Document Type: Article

References (37)

1. Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet 2009;373:1119-32.
2. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-81. (Pubitemid 46849157)
3. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449-56.
4. Dutcher JP, de Souza P, McDermott D, Figlin RA, Berkenblit A, Thiele A, et al. Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol 2009;26:202-9.
5. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010;116:4256-65.
6. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883-92.
7. Yap TA, Gerlinger M, Futreal PA, Pusztai L, Swanton C. Intratumor heterogeneity: seeing the wood for the trees. Sci Transl Med 2012;4:127ps10.
8. Amato RJ, Jac J, Giessinger S, Saxena S, Willis JP. A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer 2009;115:2438-46.
9. Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004;22:909-18. (Pubitemid 41103603)
10. Molina AM, Ginsberg MS, Motzer RJ. Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib. Med Oncol 2010;28:1527-9.
11. Gnirke A, Melnikov A, Maguire J, Rogov P, LeProust EM, Brockman W, et al. Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. Nat Biotechnol 2009;27:182-9.
12. Wagle N, Berger MF, Davis MJ, Blumenstiel B, Defelice M, Pochanard P, et al. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov 2012;2:82-93.
13. Yang H, Rudge DG, Koos JD, Vaidialingam B, Yang HJ, Pavletich NP. mTOR kinase structure, mechanism and regulation. Nature 2013;497:217-23.
14. Figlin RA, de Souza P, McDermott D, Dutcher JP, Berkenblit A, Thiele A, et al. Analysis of PTEN and HIF-1alpha and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-alpha. Cancer 2009;115:3651-60.
15. Cho D, Signoretti S, Dabora S, Regan M, Seeley A, Mariotti M, et al. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 2007;5:379-85. (Pubitemid 47584475)
16. Antonescu CR. The GIST paradigm: lessons for other kinase-driven cancers. J Pathol 2011;223:251-61.
17. Romano E, Schwartz GK, Chapman PB, Wolchock JD, Carvajal RD. Treatment implications of the emerging molecular classification system for melanoma. Lancet Oncol 2011;12:913-22.
18. Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med 2013;137:828-60.
19. Di Nicolantonio F, Arena S, Tabernero J, Grosso S, Molinari F, Macarulla T, et al. Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest 2010;120:2858-66.
20. Ihle NT, Lemos R Jr., Wipf P, Yacoub A, Mitchell C, Siwak D, et al. Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res 2009;69:143-50.
21. Tanaka H, Yoshida M, Tanimura H, Fujii T, Sakata K, Tachibana Y, et al. The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations. Clin Cancer Res 2011;17:3272-81.
22. Hanrahan AJ, Schultz N, Westfal ML, Sakr RA, Giri DD, Scarperi S, et al. Genomic complexity and AKT dependence in serous ovarian cancer. Cancer Discov 2012;2:56-67.
23. Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, Tsimberidou AM, et al. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol 2012;30:777-82.
24. Iyer G, Hanrahan AJ, Milowsky MI, Al-Ahmadie H, Scott SN, Janakiraman M, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science 2012;338:221.
25. Kucejova B, Pena-Llopis S, Yamasaki T, Sivanand S, Tran TA, Alexander S, et al. Interplay between pVHL and mTORC1 pathways in clear-cell renal cell carcinoma. Mol Cancer Res 2011;9:1255-65.
26. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012;2:401-4.
27. Cancer Genome Atlas Research N. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013;499:43-9.
28. Krueger DA, Care MM, Holland K, Agricola K, Tudor C, Mangeshkar P, et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 2010;363:1801-11.
29. Bissler JJ, Kingswood C, Zonnenberg B, Frost M, Belousova E, Radzikowska E, et al. Everolimus therapy for angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: final results from EXIST-2. J Am Soc Nephrol 2011;22 (abstr LB-PO3159).
30. Xu X, Hou Y, Yin X, Bao L, Tang A, Song L, et al. Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor. Cell 2012;148:886-95.
31. Swanton C. Intratumor heterogeneity: evolution through space and time. Cancer Res 2012;72:4875-82.
32. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004;10:789-99. (Pubitemid 39070849)
33. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
34. Gatenby RA, Gillies RJ, Brown JS. Of cancer and cave fish. Nat Rev Cancer 2011;11:237-8.
35. Hakimi AA, Chen YB, Wren J, Gonen M, Abdel-Wahab O, Heguy A, et al. Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma. Eur Urol 2013;63:848-54.
36. Hakimi AA, Ostrovnaya I, Reva BA, Schultz N, Chen YB, Gonen M, et al. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network. Clin Cancer Res 2013;19:3259-67.
37. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell 2012;149:274-93.